| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698065 | Clinical Oncology | 2016 | 6 Pages |
Abstract
The goal of re-programming the host immune system to target malignancy with durable anti-tumour clinical responses has been speculated for decades. In the last decade such speculation has been transformed into reality with unprecedented and durable responses to immune checkpoint inhibitors seen in solid tumours. This mini-review considers the mechanism of action of immune modulating agents and the potential for combination with radiotherapy in the treatment of non-small cell lung cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
G.G. Hanna, T. Illidge,